T. Rowe Price Associates
AUPH icon

T. Rowe Price Associates’s Aurinia Pharmaceuticals AUPH Stock Holding History

T. Rowe Price Associates’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.69M Buy
99,276
+13,054
+15% +$209K ﹤0.01% 2093
2026
Q1 		$1.28M Buy
86,222
+18,816
+28% +$275K ﹤0.01% 2026
2025
Q4 		$1.08M Buy
67,406
+5,120
+8% +$72.6K ﹤0.01% 2054
2025
Q3 		$689K Buy
62,286
+3,630
+6% +$39.6K ﹤0.01% 2234
2025
Q2 		$497K Sell
58,656
-382
-0.6% -$3.06K ﹤0.01% 2302
2025
Q1 		$475K Buy
59,038
+6,940
+13% +$56.2K ﹤0.01% 2265
2024
Q4 		$468K Buy
52,098
+8,350
+19% +$68.1K ﹤0.01% 2311
2024
Q3 		$321K Sell
43,748
-1,959
-4% -$12.1K ﹤0.01% 2447
2024
Q2 		$261K Buy
45,707
+6,755
+17% +$35.6K ﹤0.01% 2488
2024
Q1 		$196K Buy
38,952
+5,079
+15% +$34.5K ﹤0.01% 2631
2023
Q4 		$305K Buy
33,873
+3,494
+12% +$28.8K ﹤0.01% 2369
2023
Q3 		$237K Buy
30,379
+2,968
+11% +$29K ﹤0.01% 2438
2023
Q2 		$266K Buy
27,411
+1,484
+6% +$15.4K ﹤0.01% 2422
2023
Q1 		$285K Buy
25,927
+2,906
+13% +$25.6K ﹤0.01% 2371
2022
Q4 		$99K Buy
23,021
+1,563
+7% +$9.07K ﹤0.01% 2720
2022
Q3 		$162K Buy
21,458
+8,659
+68% +$75K ﹤0.01% 2609
2022
Q2 		$129K Buy
+12,799
New +$143K ﹤0.01% 2706
2017
Q2 		– Sell
-751,300
Closed -$5.51M – 2559
2017
Q1 		$5.51M Buy
+751,300
New +$3.47M ﹤0.01% 1416

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates's AUPH Position: Q2 2026 in Review

T. Rowe Price Associates increased its Aurinia Pharmaceuticals (AUPH) stake by 15% in Q2 2026, buying an estimated $209K and bringing the position to 99,276 shares worth $1.69M. The position accounts for ﹤0.01% of the portfolio, ranked #2093.

T. Rowe Price Associates first reported a position in AUPH in Q1 2017 and has held it in 18 quarters since. The position peaked at $5.51M in Q1 2017. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • T. Rowe Price Associates held 99,276 shares of Aurinia Pharmaceuticals worth $1.69M as of Q2 2026.
  • T. Rowe Price Associates bought 13,054 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $209K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2093 holding.
  • T. Rowe Price Associates first reported a position in Aurinia Pharmaceuticals in Q1 2017 and has held it in 18 quarters since.
  • T. Rowe Price Associates's Aurinia Pharmaceuticals position peaked at $5.51M in Q1 2017.
  • 282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.